Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 41 to 50 of 1849 total matches.
Olanzapine for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 19, 1997 (Issue 992)
inpatients with schizophrenia,
three dose-ranges of olanzapine, 5 ± 2.5 mg/day, 10 ± 2.5 mg/day and 15 ± 2.5 ...
Olanzapine (Zyprexa - Lilly), a thienobenzodiazepine that structurally resembles and binds to many of the same receptors as clozapine (Clozaril), is now available in the USA for treatment of schizophrenia and other psychotic disorders.
Topical Penciclovir for Herpes Labialis
The Medical Letter on Drugs and Therapeutics • Jun 20, 1997 (Issue 1003)
daily) for four days. One trial in 1,573 treated patients
found that the time to loss of pain was 3.5 ...
Penciclovir 1% cream (Denavir - SmithKline Beecham) has been approved by the US Food and Drug Administration (FDA) for treatment of recurrent orolabial herpes simplex virus (HSV) infections in adults. Acyclovir (Zovirax) is also available in a topical formulation for treatment of herpes simplex infections, but is approved by the FDA only for use in immunocompromised patients. Oral drugs approved for treatment of some herpes simplex infections, but not recurrent orolabial infections, include acyclovir, valacyclovir (Valtrex) and famciclovir (Famvir), which is rapidly hydrolyzed to...
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
daily for
up to 14 days while hospitalized, in addition to IV
treatment with the antiviral drug ...
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
corresponding to
30 kg/m2 for adults
3 mg SC once/day
Titration: 0.6 mg once/day x 7 days;
increase in 0.6 ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3 doi:10.58347/tml.2024.1708c | Show Introduction Hide Introduction
COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
(Veklury) has now
been FDA-approved for treatment of COVID-19 in
patients ≥28 days old who weigh ≥3 kg ...
IV antiviral drug remdesivir (Veklury) has now been FDA-approved for treatment of COVID-19 in patients ≥28 days old who weigh ≥3 kg and are either hospitalized or at high risk for progression to severe disease. Remdesivir was already FDA-approved for these indications in patients ≥12 years old who weigh ≥40 kg; it was available under an Emergency Use Authorization (EUA) for younger or lighter patients. Remdesivir is the first drug to be FDA-approved for treatment of COVID-19 in children <12 years old.
Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
once (1500 mg max) or 15 mg/
kg (1000 mg max) on day 1
and 7.5 mg/kg (500 mg max)
on day 82
6 - ...
View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections
Azelastine Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 09, 1997 (Issue 1000)
symptoms than placebo
and as effective as beclomethasone dipropionate spray 200 µg/day ...
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray (Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal sprays are also available for this indication (Medical Letter, 37:5, 1995). Cromolyn sodium (Nasalcrom) has now been approved for over-the-counter use.
Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
after first salvage therapy or beyond. Patients received blinatumomab 9 mcg/day IV for 7 days, followed ...
The FDA has approved blinatumomab (Blincyto –
Onyx/Amgen) for treatment of relapsed or refractory
Philadelphia chromosome-negative (Ph-) B-cell precursor
acute lymphoblastic leukemia (ALL).
Toremifene and Letrozole for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Apr 10, 1998 (Issue 1024)
Aminoglutethimide − Cytadren (Novartis) 250 mg PO qid 135.43
* Cost to the pharmacist for 30 days’ treatment based ...
The antiestrogen toremifene (Fareston - Schering) and the selective aromatase inhibitor letrozole (Femara - Novartis) have been approved by the FDA for treatment of advanced breast cancer in postmenopausal women.
Valacyclovir (Valtrex) for Oral Herpes
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
(Valtrex − GlaxoSmithKline) was recently approved by the FDA for one-day
oral treatment of patients ...
Valacyclovir (Valtrex - GlaxoSmithKline) was recently approved by the FDA for one-day oral treatment of patients at least 12 years old with orolabial herpes simplex infections. The drug was previously approved for treatment and suppression of genital herpes and for treatment of herpes zoster (shingles).